Dec 31, 2025 • openPR.com
SOMEWHAT-BULLISH
Disposable Insulin Pumps Market is expected to reach US$ 6.9 billion by 2032 | Major Companies - Medtronic, Roche, Animas Corporation, Tandem Diabetes Care.
The Global Disposable Insulin Pumps Market is projected to grow from US$ 3.83 billion in 2024 to US$ 6.9 billion by 2032, exhibiting a CAGR of 7.76%. This growth is driven by recent innovations and increasing adoption of tubeless patch pumps for diabetes management in regions like the US and Europe. Key players in this market include Medtronic, Insulet Corporation, and Roche.
Dec 30, 2025 • TipRanks
NEUTRAL
Tandem Diabetes Care Updates Bylaws, Tightens Governance Rules
Tandem Diabetes Care's board updated its bylaws on December 26, 2025, to strengthen governance rules, particularly concerning shareholder nomination procedures and proxy processes. These changes aim to streamline corporate governance, formalize the board's control over shareholder meetings, and align with Delaware corporate law. The move may influence future interactions with activist investors and other shareholders.
Dec 29, 2025 • 富途牛牛
SOMEWHAT-BULLISH
Favourable Signals For Tandem Diabetes Care: Numerous Insiders Acquired Stock
Multiple insiders at Tandem Diabetes Care (NASDAQ:TNDM) have recently purchased stock, sending a positive signal to shareholders. While these purchases were made at prices below the current market value, they suggest insiders see value in the company and are aligning their interests with other shareholders. The Executive VP & COO, Jean-Claude Kyrillos, made the largest recent purchase of US$191k worth of shares at US$18.12 each.
Dec 25, 2025 • PR Newswire
NEUTRAL
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM
Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. (NASDAQ: TNDM) following allegations that the company issued materially misleading business information. This investigation comes after Tandem Diabetes announced a voluntary medical device correction for select t:slim X2 insulin pumps due to a speaker-related issue that can halt insulin delivery, causing a 19.9% stock drop. The firm encourages investors who purchased Tandem Diabetes securities to join a prospective class action to recover losses.
Dec 23, 2025 • Fox 59
NEUTRAL
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM
The Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. (NASDAQ: TNDM) following a voluntary medical device correction for select t:slim X2 insulin pumps, which caused the company's stock to fall by 19.9%. Investors who purchased Tandem Diabetes securities are encouraged to contact the firm to inquire about joining a prospective class action to recover losses. The firm highlights its track record in securities class actions and shareholder derivative litigation.
Dec 23, 2025 • openPR.com
BULLISH
Artificial Pancreas System Market is set for steady growth to US$ 2070.82 million by 2033 at a CAGR of 18.0% | Key Players:Medtronic Plc, Tandem Diabetes Care, Inc., Beta Bionics.
The global Artificial Pancreas System market, valued at US$ 456.97 million in 2024, is projected to reach US$ 2070.82 million by 2033, demonstrating an 18.0% CAGR. This growth is fueled by the rising prevalence of diabetes, increased adoption of automated insulin delivery systems, and advancements in sensor technologies. Key players like Medtronic Plc, Tandem Diabetes Care, Inc., and Beta Bionics are driving innovation, with North America currently holding the largest market share.